{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T22:46:58Z","timestamp":1749336418619,"version":"3.37.3"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1038\/s41375-024-02177-y","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T12:03:11Z","timestamp":1708344191000},"page":"676-678","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of karyotype scoring guidelines for evaluating karyotype complexity in chronic lymphocytic leukemia"],"prefix":"10.1038","volume":"38","author":[{"given":"Matthew R.","family":"Avenarius","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4891-6144","authenticated-orcid":false,"given":"Adam S.","family":"Kittai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema A.","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry A.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Grever","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3403-9144","authenticated-orcid":false,"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6110-6069","authenticated-orcid":false,"given":"Cecelia R.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"2177_CR1","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/ajh.25956","volume":"95","author":"L Jondreville","year":"2020","unstructured":"Jondreville L, Krzisch D, Chapiro E, Nguyen-Khac F. The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations. Am J Hematol. 2020;95:1361\u20137.","journal-title":"Am J Hematol"},{"key":"2177_CR2","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","volume":"133","author":"P Baliakas","year":"2019","unstructured":"Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F, et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood. 2019;133:1205\u201316. https:\/\/doi.org\/10.1182\/blood-2018-09-873083.","journal-title":"Blood"},{"key":"2177_CR3","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1182\/blood.2020010536","volume":"138","author":"AS Kittai","year":"2021","unstructured":"Kittai AS, Miller C, Goldstein D, Huang Y, Abruzzo LV, Beckwith K, et al. The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. Blood. 2021;138:2372\u201382.","journal-title":"Blood"},{"key":"2177_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.leukres.2009.07.006","volume":"34","author":"K Chun","year":"2010","unstructured":"Chun K, Hagemeijer A, Iqbal A, Slovak ML. Implementation of standardized international karyotype scoring practices is needed to provide uniform and systematic evaluation for patients with myelodysplastic syndrome using IPSS criteria: An International Working Group on MDS Cytogenetics Study. Leuk Res. 2010;34:160\u20135.","journal-title":"Leuk Res"},{"key":"2177_CR5","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s41375-022-01561-w","volume":"36","author":"F Nguyen-Khac","year":"2022","unstructured":"Nguyen-Khac F, Bidet A, Daudignon A, Lafage-Pochitaloff M, Ameye G, Bilhou-Nabera C, et al. The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH). Leukemia. 2022;36:1451\u201366.","journal-title":"Leukemia"},{"key":"2177_CR6","doi-asserted-by":"crossref","unstructured":"McGowan-Jordan J, Hastings RJ, Moore S (eds). ISCN 2020: an International System for Human Cytogenomic Nomenclature (2020). S. Karger AG, Basel, 2020.","DOI":"10.1159\/isbn.978-3-318-06867-2"},{"key":"2177_CR7","doi-asserted-by":"publisher","first-page":"788761","DOI":"10.3389\/fonc.2021.788761","volume":"11","author":"T Chatzikonstantinou","year":"2021","unstructured":"Chatzikonstantinou T, Demosthenous C, Baliakas P. Biology and treatment of high-risk CLL: significance of complex karyotype. Front Oncol. 2021;11:788761.","journal-title":"Front Oncol"},{"key":"2177_CR8","first-page":"103410","volume":"71","author":"F Nguyen-Khac","year":"2023","unstructured":"Nguyen-Khac F, Balogh Z, Chauzeix J, Veronese L, Chapiro E. Cytogenetics in the management of chronic lymphocytic leukemia: Guidelines from the Groupe Francophone de Cytog\u00e9n\u00e9tique H\u00e9matologique (GFCH). Curr Res Transl Med. 2023;71:103410.","journal-title":"Curr Res Transl Med"},{"key":"2177_CR9","doi-asserted-by":"publisher","first-page":"e707","DOI":"10.1097\/HS9.0000000000000707","volume":"6","author":"P Baliakas","year":"2022","unstructured":"Baliakas P, Espinet B, Mellink C, Jarosova M, Athanasiadou A, Ghia P, et al. Cytogenetics in chronic lymphocytic leukemia: ERIC perspectives and recommendations. Hemasphere. 2022;6:e707.","journal-title":"Hemasphere"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02177-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02177-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02177-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T14:10:31Z","timestamp":1709561431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02177-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2177"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02177-y","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"type":"print","value":"0887-6924"},{"type":"electronic","value":"1476-5551"}],"subject":[],"published":{"date-parts":[[2024,2,19]]},"assertion":[{"value":"1 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ASK receives research funding from AstraZeneca and BeiGene, and has consulted for Abbvie, AstraZeneca, Beigene, BMS, Kite\/Gilead, Janssen, and LOXO@Lilly, and is on the speaker\u2019s bureau for BeiGene. SAB consulted for Pharmacyclics, Janssen, BeiGene, and AstraZeneca; received an honorarium from OncLive; and received a travel grant from ArQule. KAR receives research funding from Genentech, AbbVie, and Novartis and consults for Pharmacyclics, Janssen, Genentech, Abbvie, AstraZeneca, BeiGene, LOXO@Lilly, and Alpine Immune Science. MRG consults for Astra Zeneca, Pharmacyclics, Ascerta, Axio. Receives research funding from Hairy Cell Leukemia Foundation for Patient Data Registry, travel funding from Hairy Cell Leukemia Foundation and scientific honorarium from University of Pittsburgh. Serves as Board Chair for Scientific Board for Hairy Cell Leukemia Foundation (no reimbursement). JAW receives research funding from Karyopharm Therapeutics, Loxo@Lilly, Schrodinger, AbbVie, and MorphoSys, and consults for ArQule, AstraZeneca, BeiGene, Janssen, Pharmacyclics, Newave, AbbVie, MorphoSys, and Genentech. CRM receives funding from AbbVie. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}